Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
January 06 2021 - 8:00AM
Business Wire
Kite, a Gilead Company (Nasdaq: GILD), and Oxford
BioTherapeutics Ltd. (OBT), a clinical stage oncology company with
a pipeline of immuno-oncology (IO) and antibody-drug conjugate
(ADC)-based therapies, announced that the companies have entered
into a research collaboration to evaluate five novel targets for a
number of hematologic and solid tumor indications.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210106005129/en/
Through this collaboration, OBT will validate five novel
oncology drug targets, previously identified using OBT’s OGAP®
discovery platform, and generate antibodies against these targets.
Kite and Gilead will have the exclusive right to develop and
commercialize therapies based on these targets or antibodies.
“As the leader in cell therapy, we are committed to continuing
to bring its transformative potential to more patients with
different kinds of cancers,” said Mert Aktar, Vice President of
Corporate Development and Strategy at Kite. “We’re excited to
partner with Oxford BioTherapeutics to help accelerate this
research by identifying new targets in solid tumors and hematologic
malignancies where novel approaches may help improve outcomes.”
Dr. Christian Rohlff, OBT’s Chief Executive Officer said,
“Selecting the right target is fundamental for the successful
development of first-in-class cell therapies. OBT’s
state-of-the-art platforms have refined this approach to address
difficult-to-treat cancers. This has resulted in several candidates
entering clinical development either by OBT or its development
partners. We are delighted that Kite, the global leader in cell
therapy, has recognized the potential of OBT’s OGAP® discovery
platform and antibody capabilities through this partnership. On
behalf of patients in urgent need of novel therapies, we look
forward to working with Kite to advance cell therapies for the
treatment of hematologic malignancies and solid tumors.”
Under the terms of the agreement, OBT will receive an upfront
payment and will be eligible to receive additional payments based
on achievement of certain discovery, clinical and regulatory
milestones, as well as royalties on future potential sales.
About Oxford
BioTherapeutics
Oxford BioTherapeutics is a clinical stage oncology company;
based in Oxford, UK; Morristown, New Jersey and San Jose,
California, USA; with a pipeline of first-in-class immuno-oncology
(IO) and antibody-drug conjugate (ADC)-based therapies identified
using OBT’s proprietary OGAP® target discovery platform. OBT’s
approach aims to fulfil major unmet patient needs by targeting
difficult-to-treat cancers. For more information on Oxford
BioTherapeutics, please visit www.oxfordbiotherapeutics.com.
About Kite
Kite, a Gilead Company, is a biopharmaceutical company based in
Santa Monica, California, with commercial manufacturing operations
in North America and Europe. Kite is engaged in the development of
innovative cancer immunotherapies. The company is focused on
chimeric antigen receptor and T cell receptor engineered cell
therapies. For more information on Kite, please visit
www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com.
Gilead and Kite Forward-Looking
Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors,
including the risk that Gilead and Kite may not realize the
potential benefits of this collaboration with Oxford
BioTherapeutics or other investments in cell therapy. All
statements other than statements of historical fact are statements
that could be deemed forward-looking statements. These risks,
uncertainties and other factors could cause actual results to
differ materially from those referred to in the forward-looking
statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2020 as filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
information currently available to Gilead and Kite, and Gilead and
Kite assume no obligation to update any such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210106005129/en/
Gilead and Kite Contacts: Monica Tellado, Investors (650)
219-3882 Nathan Kaiser, Media (650) 522-1853 OBT Contacts:
Investors: Christian Rohloff CEO, Oxford BioTherapeutics 44 (0)
1235 861770 christian.r@oxfordbiotherapeutics.com Media: Ryo
Imai 212-213-0006, ext. 315 rimai@burnsmc.com Robert Flamm, Ph.D.
212-213-0006, ext. 364 rflamm@burnsmc.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024